Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain from Bank of America Securities reiterated a Buy rating on the stock and has a €123.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sachin Jain has given his Buy rating due to a combination of factors, primarily focusing on Sanofi’s promising drug pipeline and undervaluation. The analyst emphasizes the potential of amlitelimab in the atopic dermatitis market, particularly as a second-line treatment, which could see significant usage if Phase III trials replicate the success of Phase II. Jain highlights the competitive edge amlitelimab might have over other treatments like rocatinlimab, due to its potentially better safety profile and efficacy.
Additionally, Jain points out that Sanofi’s stock is undervalued, with a projected earnings growth that is not fully reflected in its current price. The anticipated growth in earnings per share from 2026 to 2029 supports this view. The analyst also notes other promising developments in Sanofi’s pipeline, such as tolebrutinib and INBRX101, which could further bolster the company’s growth prospects. These factors collectively underpin the Buy rating, with a price objective set significantly higher than the current trading price.
Jain covers the Healthcare sector, focusing on stocks such as AstraZeneca, Sanofi, and Novo Nordisk. According to TipRanks, Jain has an average return of 1.2% and a 48.48% success rate on recommended stocks.
In another report released on June 12, Berenberg Bank also maintained a Buy rating on the stock with a €118.00 price target.